Pharmacodynamics and pharmacokinetic-pharmacodynamic relationships of atovarstatin, an HMG-CoA reductase inhibitor

Journal of Clinical Pharmacology

Volumn 40, Issue 6, 2000, Pages 616-623

  Stern, Ralph H ^a   Yang, Bing Bing ^c   Hounslow, Neil J ^a   MacMahon, Mark ^b   Abel, Robert B ^a   Olson, Stephen C ^a  

^a PFIZER INC   (United States)

^b Chiltern International Ltd   (United Kingdom)

^c Chiltern International Ltd ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; FIRST PASS EFFECT; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID METABOLISM;

EID: 0033673496     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.2000.tb05987.x     Document Type: Article

References (12)

1. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects
2. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
3. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects
4. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
5. Development and validation of an enzyme inhibition assay for quantitation of CI-981 in human plasma
6. Plasma mevalonate as a measure of cholesterol synthesis in man
7. Lovastatin treatment inhibits sterol synthesis and induces HMG-CoA reductase activity in mononuclear leukocytes of normal subjects
8. Rate of low-density lipoprotein cholesterol and apolipoprotein B changes on initiation and discontinuation of atorvastatin treatment
9. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase
10. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
11. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia